New treatment target found for ‘poorly differentiated thyroid cancer (PDTC)
SNUH researchers (Prof. Sunwook Cho, Youngjoo Park, Youngshin Song’s team) first revealed the effects of cancer growth caused by thyroid-stimulating hormone (TSH) at poorly differentiated thyroid cancer (PDTC), which is difficult to treat. The procedure, thyroid-stimulating hormone (TSH) suppression, is widely used to treat well-differentiated thyroid cancer, whereas its role in poorly differentiated thyroid cancer (PDTC) was undetermined.
* Thyroid hormone, made from the thyroid gland and released into the blood, plays a very important role in the body, maintaining a constant function of the body and causing the metabolism to return actively.
In addition to controlling thyroid hormone, TSH is also involved in the activities of thyroid cancer cells. Increased concentrations of thyroid hormone activate thyroid cancer cells, which is why patients with thyroid cancer undergo 'suppression thyroid hormone procedure' to prevent cancer from recurring after surgery.
"We have established a basis for the need for thyroid stimulating hormone suppressing therapy in PDTC," said Professor Sunwook Cho, who said, "Further clinical studies should be conducted to confirm the practical effects."
For more details, please see http://clincancerres.aacrjournals.org/content/early/2018/11/12/1078-0432.CCR-18-0663